Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
Abstract
:1. Rationale for Breast Screening
2. Screening Mammography
3. Magnetic Resonance Imaging (MRI)
4. Is MRI Sufficient for Breast Screening?
5. Age to Start and Stop Screening and Optimal Screening Interval
6. Survival of Screened BRCA Mutation Carriers Who Develop Breast Cancer
7. Novel Imaging Modalities
8. Conclusions
Conflicts of Interest
References
- Sigal, B.M.; Munoz, D.F.; Kurian, A.W.; Plevritis, S.K. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA1 mutation carriers. Cancer Epidemiol. Biomark. Prev. 2012, 21, 1066–1077. [Google Scholar] [CrossRef] [PubMed]
- Marmot, M.G.; Altman, D.G.; Cameron, D.A.; Dewar, J.A.; Thompson, S.; Wilcox, M. The benefits and harms of breast cancer screening: An independent review. Independent UK panel on breast cancer screening. Lancet 2012, 380, 1778–1786. [Google Scholar] [CrossRef]
- Burke, W.; Daly, M.; Garber, J.; Botkin, J.; Kahn, M.J.; Lynch, P.; McTiernan, A.; Offit, K.; Perlman, J.; Petersen, G.; et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer II. BRCA 1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997, 277, 997–1003. [Google Scholar] [CrossRef] [PubMed]
- Brekelmans, C.T.M.; Seynaeve, C.; Bartels, C.C.; Tilanus-Linthorst, M.M.; Meijers-Heijboer, E.J.; Crepin, C.M.; van Geel, A.A.; Menke, M.; Verhoog, L.C.; van den Ouweland, A.; et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J. Clin. Oncol. 2001, 19, 924–930. [Google Scholar] [CrossRef] [PubMed]
- Scheuer, L.; Kauff, N.; Robson, M.; Kelly, B.; Barakat, R.; Satagopan, J.; Ellis, N.; Hensley, M.; Boyd, J.; Borgen, P.; Norton, L.; Offit, K. Outcomes of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J. Clin. Oncol. 2002, 20, 1260–1268. [Google Scholar] [CrossRef] [PubMed]
- Vasen, H.F.A.; Tesfay, E.; Bonnstra, H.; Mourits, M.J.; Rutgers, E.; Verheyen, R.; Oosterwijk, J.; Beex, L. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur. J. Cancer. 2005, 41, 549–554. [Google Scholar] [CrossRef] [PubMed]
- Komenaka, I.K.; Ditkoff, B.; Joseph, K.; Russo, D.; Gorroochurn, P.; Ward, M.; Horowitz, E.; El-Tamer, M.B.; Schnabel, F.R. The development of interval breast malignancies in patients with BRCA Mutations. Cancer 2004, 100, 2079–2083. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, R.D.; Hunt, W.C.; Williamson, M.R.; Gilliland, F.D.; Wiest, P.W.; Kelsey, C.A.; Key, C.R.; Linver, M.N. Effects of age, breast density, ethnicity and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: Review of 183,134 screening mammograms in Albuquerque, NM. Radiology 1998, 209, 511–518. [Google Scholar] [CrossRef] [PubMed]
- Chang, J.; Yang, W.T.; Choo, H.F. Mammography in Asian patients with BRCA1 mutations (letter). Lancet 1999, 353, 2070–2071. [Google Scholar] [CrossRef]
- Goffin, J.; Chappuis, P.O.; Wong, N.; Foulkes, W.D. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer (letter). J. Nat. Cancer Inst. 2001, 93, 1754–1755. [Google Scholar] [CrossRef] [PubMed]
- Lakhani, S.R.; Jacquemier, J.; Sloane, J.P.; Gusterson, B.A.; Anderson, T.J.; van de Vijver, M.J.; Farid, L.M.; Venter, D.; Antoniou, A.; Storfer-Isser, A.; et al. Multifactorial analysis of differences between sporadic breast cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998, 90, 1138–1145. [Google Scholar] [CrossRef] [PubMed]
- Marcus, J.N.; Watson, P.; Page, D.L.; Narod, S.A.; Lenoir, G.M.; Tonin, P.; Linder-Stephenson, L.; Salerno, G.; Conway, T.A.; Lynch, H.T. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996, 77, 697–709. [Google Scholar] [CrossRef]
- Tilanus-Linthorst, M.M.; Obdeijn, I.M.; Hop, W.C.J.; Causer, P.A.; Leach, M.O.; Warner, E.; Pointon, L.; Hill, K.A.; Klijn, J.G.M.; Warren, R.M.L.; et al. A BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, UK, and Canadian MRI screening trials. Clin. Cancer Res. 2007, 13, 7357–7362. [Google Scholar] [CrossRef] [PubMed]
- Morris, E.A. Diagnostic breast MRI imaging. Current status and future directions. Magn. Reson. Imaging Clin. N. Am. 2010, 18, 57–74. [Google Scholar] [CrossRef] [PubMed]
- Heywang-Kobrunner, S.H.; Hacker, A.; Sedlacek, S. Magnetic resonance imaging: The evolution of breast imaging. Breast 2013, 3, S77–S82. [Google Scholar] [CrossRef] [PubMed]
- Warner, E.; Messersmith, H.; Causer, P.; Eisen, A.; Shumak, R.; Plewes, D. Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann. Int. Med. 2008, 148, 671–679. [Google Scholar] [CrossRef] [PubMed]
- Clinical guideline. Familial Breast Cancer: Classification, care and managing breast cancer and related risks in people with a family history of breast cancer (last update March 2017). Available online: www.nice.org.uk/guidance/cg164 (accessed on 21 October, 2018).
- Daly, M.B.; Pilarski, R; Berry, M.P.; Buys, S.S; Friedman, S.; Garber, J.E; Hutton, M.L.; Kauff, N.D.; Kahn, S.; Klein, C.; et al. Genetic/familial high risk assessment: Breast and ovarian. (Version 2.2019, July 2018). Available online: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (accessed on 2 September 2018).
- Paluch-Shimon, S.; Cardoso, F.; Sessa, C.; Balmana, J.; Cardoso, M.J.; Gilbert, F.; Senkus, E.; ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 2016, 27, v103–v110. [Google Scholar] [CrossRef] [PubMed]
- Warner, E.; Messersmith, H.; Causer, P.; Eisen, A.; Shumak, R.; Plewes, D. Magnetic Resonance Imaging screening of women at high risk for breast cancer v.3. (last update January 2018). Available online: www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/2051 (accessed on 2 September 2018).
- Sardanelli, F.; Boetes, C.; Borisch, B.; Decker, T.; Federico, M.; Gilbert, F.J.; Helbich, T.; Heywang-Köbrunner, S.H.; Kaiser, W.A.; Kerin, M.J.; et al. Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group. Eur. J. Cancer 2010, 46, 1296–1315. [Google Scholar] [CrossRef] [PubMed]
- Warner, E.; Plewes, D.B.; Hill, K.A.; Causer, P.A.; Zubovits, J.T.; Jong, R.A.; Cutrara, M.R.; DeBoer, G.; Yaffe, M.J.; Messner, S.J.; Meschino, W.S.; et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292, 1317–1325. [Google Scholar] [CrossRef] [PubMed]
- Pinsky, P.F.; Bellinger, C.R.; Miller, D.P. False-positive screens and lung cancer risk in the National Lung Screening Trial: Implications for shared decision-making. J. Med. Screen 2018, 25, 110–112. [Google Scholar] [CrossRef] [PubMed]
- Kanal, E. Gadolinium based contrast agents (GBCA); safety review after three decades of clinical experience. Magn. Reson. Imaging 2016, 34, 1341–1345. [Google Scholar] [CrossRef] [PubMed]
- Radbruch, A.; Weberling, L.D.; Kieslich, P.J.; Eidel, O.; Burth, S.; Kickingereder, P.; Heiland, S.; Wick, W.; Schlemmer, H.P.; Bendszus, M. Gadolinium retention in the dentate nucleus and globus pallidis is dependent on the contrast agent. Radiology 2015, 275, 783–795. [Google Scholar] [CrossRef] [PubMed]
- Tedeschi, E.; Caranci, F.; Giordano, F.; Angelini, V.; Cocozza, S.; Brunetti, A. Gadolinium retention in the body: What we know and what we can do. Radiol. Med. 2017, 122, 589–600. [Google Scholar] [CrossRef] [PubMed]
- Chiarelli, A.M.; Prummel, M.V.; Muradali, D.; Majpruz, V.; Horgan, M.; Carroll, J.C.; Eisen, A.; Meschino, W.S.; Shumak, R.S.; Warner, E.; Rabeneck, L. Effectiveness of screening with annual magnetic resonance imaging and mammography: Results of the initial screen from the Ontario High Risk Breast Screening Program. J. Clin. Oncol. 2014, 32, 2224–2230. [Google Scholar] [CrossRef] [PubMed]
- Powell, S.N.; Kachnic, L.A. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003, 22, 5784–5791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pijpe, A.; Andrieu, N.; Easton, D.F.; Kesminiene, A.; Cardis, E.; Noguès, C.; Gauthier-Villars, M.; Lasset, C.; Fricker, J.P.; Peock, S.; et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: Retrospective cohort study (GENE-RAD-RISK). Br. Med. J. 2012, 345, e5660. [Google Scholar] [CrossRef] [PubMed]
- Giannakeas, V.; Lubinsky, J.; Gronwald, J.; Moller, P.; Armel, S.; Lynch, H.T.; Foulkes, W.D.; Kim-Sing, C.; Singer, C.; Newhausen, S.L.; et al. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carrier; a prospective study. Breast Cancer Res. Treat. 2014, 147, 113–118. [Google Scholar] [CrossRef] [PubMed]
- Obdeijn, I.M.; Winter-Warnars, G.A.; Mann, R.M.; Hooning, M.J.; Hunink, M.G.; Tilanus-Linthorst, M.M. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. Breast Cancer Res. Treat. 2014, 144, 577–582. [Google Scholar] [CrossRef] [PubMed]
- Vreemann, S.; van Zelst, J.C.M.; Schlooz-Vries, M.; Bult, P.; Hoogerbrugge, N.; Karssemeijer, N.; Gubern-Merida, A.; Mann, R.M. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI. Breast Cancer Res. 2018, 20, 84. [Google Scholar] [CrossRef] [PubMed]
- Sardanelli, F.; Santoro, F.; Podo, F. Screening high risk women with MRI alone? Eur. J. Radiol. 2012, 81 (Suppl. 1), S137–S138. [Google Scholar] [CrossRef]
- Lehman, C.D.; Isaacs, C.; Schnall, M.D.; Pisano, E.D.; Ascher, S.M.; Weatherall, P.T.; Bluemke, D.A.; Bowen, D.J.; Marcom, P.K.; Armstrong, D.K.; et al. Cancer yield of mammography, MR, and US in high-risk women: Prospective mutli-institution breast cancer screening study. Radiology 2007, 244, 381–388. [Google Scholar] [CrossRef] [PubMed]
- Sardanelli, F.; Podo, F.; Santoro, F.; Manoukian, S.; Bergonzi, S.; Trecate, G.; Vergnaghi, D.; Federico, M.; Cortesi, L.; Corcione, S.; et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the High Breast Cancer Risk Italian 1 study): Final results. Investig. Radiol. 2010, 46, 94–105. [Google Scholar] [CrossRef] [PubMed]
- Riedl, C.C.; Luft, N.; Bernhart, C.; Weber, M.; Bernathova, M.; Tea, M.K.; Rudas, M.; Singer, C.F.; Helbich, T.H. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J. Clin. Oncol. 2015, 33, 1128–1135. [Google Scholar] [CrossRef] [PubMed]
- Kuhl, C.K.; Schrading, S.; Leutner, C.C.; Morakkabati-Spitz, N.; Wardelmann, E.; Fimmers, R.; Kuhn, W.; Schild, H.H. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of woman at high familial risk for breast cancer. J. Clin. Oncol. 2005, 23, 8469–8476. [Google Scholar] [CrossRef] [PubMed]
- Trecate, G.; Vergnanghi, D.; Manoukian, S.; Bergonzi, S.; Scaperrotta, G.; Marchesini, M.; Ferranti, C.; Peissel, B.; Spatti, G.; Bohm, S.; et al. MRI in the early detection of breast cancer in women with high genetic risk. Tumori 2006, 92, 517–523. [Google Scholar] [PubMed]
- Kriege, M.; Brekelmans, C.T.; Boetes, C.; Besnard, P.E.; Zonderland, H.M.; Obdeijn, I.M.; Manoliu, R.A.; Kok, T.; Peterse, H.; Tilanus-Linthorst, M.M.; et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med. 2004, 351, 427–437. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.H.; Dershaw, D.D.; Kopans, D.; Evans, P.; Monsees, B.; Monticciolo, D.; Brenner, R.J.; Bassett, L.; Berg, W.; Feig, S.; et al. Breast cancer screening with imaging: Recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J. Am. Coll. Radiol. 2010, 7, 18–27. [Google Scholar] [CrossRef] [PubMed]
- Leung, J.W. Utility of second-look ultrasound in the evaluation of MRI-detected breast lesions. Semin. Roentgenol. 2011, 46, 260–274. [Google Scholar] [CrossRef] [PubMed]
- Phi, X.A.; Saadatmand, S.; De Bock, G.H.; Warner, E.; Sardanelli, F.; Leach, M.O.; Riedl, C.C.; Trop, I.; Hooning, M.J.; Mandel, R.; et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: Individual patient data meta-analysis. Br. J. Cancer 2016, 114, 631–637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bigenwald, R.Z.; Warner, E.; Gunesakar, A.; Hill, K.A.; Causer, P.; Messner, S.J.; Eisen, A.; Plewes, D.B.; Narod, S.A.; Zhang, L.; Yaffe, M.J. Is mammography adequate for screening women with inherited BRCA mutations and low breast density? Cancer Epidemiol. Biomark. Prev. 2008, 17, 706–711. [Google Scholar] [CrossRef] [PubMed]
- Nelson, H.D.; O’Meara, E.S.; Kerlikowske, K.; Balch, S.; Miglioretti, D. Factors associated with rates of false-positive and false-negative results from digital mammography screening: An analysis of registry data. Ann. Intern. Med. 2016, 164, 226–235. [Google Scholar] [CrossRef] [PubMed]
- Rijnsburger, A.J.; Obdeijn, I.M.; Kaas, R.; Tilanus-Linthorst, M.M.; Boetes, C.; Loo, CE.; Wasser, M.N.; Bergers, E.; Kok, T.; Muller, S.H.; et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: Long-term follow-up of the Dutch MRISC screening study. J. Clin. Oncol. 2010, 28, 5265–5273. [Google Scholar] [CrossRef] [PubMed]
- Chereau, E.; Uzan, C.; Balleyguider, C.; Chevalier, J.; de Paillerets, BB.; Caron, O.; Rimareix, F.; Mathieu, M.C.; Koskas, M.; Bourgier, C.; et al. Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including Magnetic Resonance Imaging. Clin. Breast Cancer 2010, 10, 113–118. [Google Scholar] [CrossRef] [PubMed]
- Shah, P.; Rosen, M.; Sopfer, J.; Siegfried, J.; Kaltman, R.; Mason, B.; Armstrong, K.; Nathanson, K.L.; Schnall, M.; Domchek, S.M. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: Effect of mutation status on cancer incidence. Breast Cancer Res. Treat. 2009, 118, 539–546. [Google Scholar] [CrossRef] [PubMed]
- Saadatmand, S.; Vos, J.R.; Hooning, M.J.; Oosterwijk, J.C.; Koppert, L.B.; de Bock, G.H.; Ausems, M.G.; van Asperen, C.J.; Aalfs, C.M.; Gómez Garcia, E.B.; et al. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study. Int. J. Cancer 2014, 135, 2940–2949. [Google Scholar] [CrossRef] [PubMed]
- Saadatmand, S.; Obdeijn, I.M.; Rutgers, E.J.; Oosterwijk, J.C.; Tollenaar, R.A.; Woldringh, G.H.; Bergers, E.; Verhoef, C.; Heijnsdijk, E.A.; Hooning, M.J.; et al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). Int. J. Cancer 2015, 137, 1729–1738. [Google Scholar] [CrossRef] [PubMed]
- Evans, D.G.; Kesavan, N.; Lim, Y.; Gadde, S.; Hurley, E.; Massat, N.J.; Maxwell, A.J.; Ingham, S.; Eeles, R.; Leach, M.O.; et al. MRI breast screening in high-risk women: Cancer detection and survival analysis. Breast Cancer Res. Treat. 2014, 145, 663–672. [Google Scholar] [CrossRef] [PubMed]
- Moller, P.; Stormorken, A.; Jonstrud, C.; Holmen, M.M.; Hagen, A.I.; Clark, N.; Vabo, A.; Sun, P.; Narod, S.A.; Maehle, L. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res. Treat. 2013, 139, 155–161. [Google Scholar] [CrossRef] [PubMed]
- Warner, E.; Zhu, S.; Hill, K.A.; Causer, P.; Jong, R.A.; Yaffe, M.; Ramsay, E.; Narod, S.; Plewes, D.B. “What if I keep my breasts?” Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer in the Toronto MRI screening study. In Proceedings of the annual meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 1–5 June 2018. [Google Scholar]
- Warner, E.; Hill, K.; Causer, P.; Plewes, D.; Jong, R.; Yaffe, M.; Foulkes, W.D.; Ghadirian, P.; Lynch, H.; Couch, F.; et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J. Clin. Oncol. 2011, 29, 1664–1669. [Google Scholar] [CrossRef] [PubMed]
- Muller, D.; Danner, M.; Rhiem, K.; Stollenwerk, B.; Engel, C.; Rasche, L.; Borsi, L.; Schmutzler, R.; Stock, S. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA1 or 2 mutation. Eur. J. Health 2018, 19, 341–353. [Google Scholar] [CrossRef] [PubMed]
- Greenwood, H.I.; Dodelzon, K.; Katzen, J.T. Impact of advancing technology on diagnosis and treatment of breast cancer. Surg. Clin. N. Am. 2018, 98, 703–724. [Google Scholar] [CrossRef] [PubMed]
- Sheth, D.; Abe, H. Abbreviated MRI and accelerated MRI for screening and diagnosis of breast cancer. Top. Magn. Reson/ Imaging 2017, 26, 183–189. [Google Scholar] [CrossRef] [PubMed]
- Jochelson, M.S.; Pinker, K.; Dershaw, D.D.; Hughes, M.; Gibbons, G.F.; Rahbar, K.; Robson, M.E.; Mangino, D.A.; Goldman, D.; Moskowitz, C.S.; Morris, E.A.; Sung, J.S. Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study. Eur. J. Radiol. 2017, 97, 37–43. [Google Scholar] [CrossRef] [PubMed]
- Yaffe, M. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Personal communication, 2018. [Google Scholar]
Organization | Annual MRI | Annual Mammography | Screening Ultrasound | Other |
---|---|---|---|---|
NCCN [18] 2018 (U.S.) | Aged 25–75 | (with consideration of tomosynthesis) Aged 30–75 Aged 25-75 if MRI not possible | Not recommended | Breast awareness aged 18+ Semi-annual CBE aged 25+ |
NICE [17] 2017 (U.K.) | Aged 30–49 Aged 50–69 only if mammo-graphically dense breasts | Aged 40–69 | Aged 30–49 if MRI not possible | Breast awareness |
ESMO [19] 2016 (Europe) | Aged 25+ | Aged 30+ | Aged 25+ if MRI not possible | Breast awareness Semi-annual CBE aged 25+ |
CCO [20] 2018 (Canada) | Aged 30–69 | Aged 30+ | Aged 30–69 if MRI not possible | Breast Awareness |
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Warner, E. Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer. Cancers 2018, 10, 477. https://doi.org/10.3390/cancers10120477
Warner E. Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer. Cancers. 2018; 10(12):477. https://doi.org/10.3390/cancers10120477
Chicago/Turabian StyleWarner, Ellen. 2018. "Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer" Cancers 10, no. 12: 477. https://doi.org/10.3390/cancers10120477
APA StyleWarner, E. (2018). Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer. Cancers, 10(12), 477. https://doi.org/10.3390/cancers10120477